A Study to Compare Human Thrombin Against Bovine Thrombin in Its Ability to Stop Bleeding After Surgery
A Comparative Evaluation of Human Thrombin Versus Bovine Thrombin in Achieving Hemostasis in Patients Undergoing Cardiovascular, Neurologic (Spine) and General Surgery Procedures.
1 other identifier
interventional
304
1 country
17
Brief Summary
The purpose of this study is to see if Human Thrombin is as effective as Bovine Thrombin in stopping surgical bleeding within 10 minutes of application.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_3
Started Nov 2004
17 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2004
CompletedFirst Submitted
Initial submission to the registry
September 12, 2005
CompletedFirst Posted
Study publicly available on registry
September 20, 2005
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2006
CompletedAugust 28, 2007
August 1, 2007
September 12, 2005
August 24, 2007
Conditions
Outcome Measures
Primary Outcomes (1)
Success in achieving hemostasis.
Secondary Outcomes (6)
Success in achieving hemostasis after application
Estimated intraoperative blood loss
Procedure duration
Time in specialty units
Length of hospital stay
- +1 more secondary outcomes
Interventions
Eligibility Criteria
You may qualify if:
- Male and female patients, of any race, 18 years or older.
- Patients who have at least one bleeding site within the operative field that is mild (oozing or capillary bleeding) to moderate (gradual or steady bleeding) in intensity and which cannot be managed by surgical modalities because they are ineffective or impractical (Change 15, Amend 1).
- Patients scheduled for any of the following elective surgical procedures:
- Cardiovascular Procedures - aortic surgery such as aneurysmectomy, aneurysmoplasty, aneurysmorrhaphy, aneurysmotomy and bypass procedures involving the aorta; major coronary bypass procedures including primary bypass surgery and re-do procedures. Peripheral vascular procedures to include femoral-popliteal bypass, femoral-femoral bypass, or other peripheral vascular procedures requiring vessel grafting with native or prosthetic grafts including Polytetrafluoroethylene (PTFE) grafts; carotid endarterectomies. The sternum is excluded as a Target Site. Bleeding sites evaluated during these procedures may include soft tissues (e.g. mammary bed, retroperitoneal fat/connective tissues and adhesions) and needle hole bleeding of prosthetic graft material (Change 6, Amend 1).
- Neurosurgical (spine) Procedures- primary lumbar laminectomy and laminectomy with fusion (fusion must be done after the time to hemostasis assessment). Re-do laminectomy, removal of tumors/lesions during laminectomy, cervical, or thoracic laminectomy procedures will be excluded. Bleeding sites evaluated may include periosteum, bone marrow, venous plexus (Change 7, Amend 1).
- General Surgery or Post-Traumatic (hemodynamically stable and non-coagulopathic) procedures: bowel and colon resections, retroperitoneal dissections/resections, and procedures involving the resection of any solid abdominal organ such as a splenectomy, liver resection, nephrectomy, splenorrhaphy, and pancreatectomy. Bleeding sites evaluated may include soft tissues (e.g. bowel mesentery, adhesions, lymph node beds, sacral venous plexus, etc.) and parenchymal organ bleeds (cut surface of resected liver, spleen, etc., excluding cut surface of kidney) (Amendment #2, Change 44). Bowel anastomoses sites will not be included (Change 8, Amend 1).
- Patient, or the patient's legally authorized representative, must provide legally effective informed consent prior to any participation in the study. (Amendment #2, Change 41)
You may not qualify if:
- Patients with bleeding diathesis, pathologic coagulopathy, systemic disorders, or autoimmune, immunodeficiency diseases or any other disorder that may interfere with hemostasis.
- Patients who have had a pre-operative laboratory finding that was considered clinically significant (as determined by the Investigator) for CBC (HCT, Hgb, white blood cell differential, platelet count, and Red Blood Cell (RBC) indices (MCH, MCV, MCHC)), prothrombin time (PT), or activated partial thromboplastin time (aPTT).
- Patients who have used anticoagulant, antiplatelet or nonsteroidal anti-inflammatory analgesic (NSAID) within 5 days prior to surgery (the use of ASA or aprotinin is permitted).
- Patients with known antibodies to bovine thrombin preparations.
- Patients receiving an organ transplant (liver, heart, kidney, etc.).
- Patients who are morbidly obese (Body Mass Index \> 35).
- Patients with acute or chronic liver failure (Amendment #2, Change 42).
- Patients with all severe (brisk or forceful) bleeding site(s).
- Patients with an ongoing infection at the operative site.
- Patients who are known alcohol and/or drug abusers.
- Female patients who are pregnant or nursing.
- Patients who have uncontrolled diabetes mellitus (blood glucose levels \>400 mg/dl) as determined by the Investigator based on medical history (Change 14, Admin. Change 2).
- Patients who have participated in another investigational drug or device research within 30 days of enrollment.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Ethicon, Inc.lead
- OMRIX Biopharmaceuticalscollaborator
Study Sites (17)
Alabama Clinical Therapeutics
Birmingham, Alabama, 35235, United States
Northwest NeuroSpecialists, PPLC
Tucson, Arizona, 85741, United States
Vacular Surgery Associates
Santa Monica, California, 90404, United States
Stanford University Medical Center
Stanford, California, 94305, United States
Ochsner Clinic
New Orleans, Louisiana, 70121, United States
Union Memorial Hospital
Baltimore, Maryland, 21218, United States
Borgess Research Institute
Kalamazoo, Michigan, 49048, United States
Washington University School of Medicine
St Louis, Missouri, 63110, United States
University of Nebrask Medical Center
Omaha, Nebraska, 68105, United States
Cooper University Hospital
Camden, New Jersey, 08103, United States
Lehigh Valley Hospital
Allentown, Pennsylvania, 18103, United States
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, 19107, United States
University of Tennessee Medical Center
Knoxville, Tennessee, 37920, United States
MD Anderson Cancer Center
Houston, Texas, 77030, United States
University of Texas Health Science Center at Houston Medical School
Houston, Texas, 77030, United States
Scott and White Hospital
Temple, Texas, 76508, United States
Neurospine Center of Wisconsin
Appleton, Wisconsin, 54913, United States
Related Publications (1)
Doria C, Fischer CP, Wood CG, Li PM, Marra S, Hart J. Phase 3, randomized, double-blind study of plasma-derived human thrombin versus bovine thrombin in achieving hemostasis in patients undergoing surgery. Curr Med Res Opin. 2008 Mar;24(3):785-94. doi: 10.1185/030079908X273426. Epub 2008 Jan 31.
PMID: 18241525DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
September 12, 2005
First Posted
September 20, 2005
Study Start
November 1, 2004
Study Completion
July 1, 2006
Last Updated
August 28, 2007
Record last verified: 2007-08